CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Revenue of CytoMed Therapeutics Limited (GDTC)
Revenue in 2023 (TTM): $384.75 K
According to CytoMed Therapeutics Limited's latest financial reports the company's current revenue (TTM) is $384.75 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of CytoMed Therapeutics Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $384.75 K | $381.92 K | $-2,624,831 | $-3,131,501 | $-3,131,788 |
| 2022 | $363.91 K | $355.19 K | $-1,495,148 | $-3,129,812 | $-3,227,956 |
| 2021 | $113.84 K | $110.34 K | $-1,607,514 | $-2,074,531 | $-2,074,531 |
| 2020 | $59.47 K | $54.84 K | $-963,718 | $-1,942,242 | $-1,942,242 |
| 2019 | $ | $ | $-474,676 | $-632,611 | $-632,611 |